SCHEMBL2670043

SCHEMBL2670043

O=Cc1ccccc1SC1CCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
KMT2A Q03164 2/20 0.44
MEN1 O00255 1/20 0.44
THRB P10828 1/20 0.44
BLM P54132 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 3/20 0.38
TSHR P16473 1/20 0.38
TRIM24 O15164 1/20 0.38
TRIM33 Q9UPN9 1/20 0.38
HPGD P15428 2/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
ALOX15 P16050 1/20 0.36
ALOX12 P18054 1/20 0.36
MC4R P32245 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SRC P12931 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6763790 0.98 LMNA (0.43) LMNAKMT2AMEN1THRBBLM
SCHEMBL2670032 0.96 MEN1 (0.41) LMNAKMT2AMEN1THRBBLM
SCHEMBL2915529 0.94 LMNA (0.46) LMNAKMT2AMEN1THRBBLM
SCHEMBL30548748 0.74 MAOA (0.44) LMNAKMT2AMEN1ALDH1A1HPGD
SCHEMBL20495594 0.74 MAOA (0.44) LMNAKMT2AMEN1ALDH1A1HPGD
SCHEMBL28787272 0.73 KMT2A (0.44) LMNAKMT2AMEN1THRBBLM
Cyclopentanamine SCHEMBL28944901 0.73 KMT2A (0.40) LMNAKMT2AMEN1THRBBLM
SCHEMBL15271555 0.72 MEN1 (0.44) LMNAKMT2AMEN1ALDH1A1TSHR
SCHEMBL29973661 0.72 HPGD (0.36) LMNAKMT2AALDH1A1HPGDMAPT
SCHEMBL2670023 0.72 HPGD (0.36) LMNAKMT2AALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168673-B2 Compounds having CRTH2 antagonist activity OXAGEN LIMITED (GB) 2012-05-01 US disclosed
EP-2240444-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY Oxagen Limited (GB) 2010-10-20 EP disclosed
WO-2009093029-A1 COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY OXAGEN LIMITED (GB) 2009-07-30 WO disclosed
US-20090192195-A1 Compounds Having CRTH2 Antagonist Activity OXAGEN LIMITED (GB) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192195-A1 Compounds Having CRTH2 Antagonist Activity HRH2, NR3C2, NR2C2 LMNA 4029/4885KMT2A 3044/4885MEN1 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.